Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Rhythm Pharmaceuticals

5 Winning US Stocks To Invest In Despite the Market Crash and Global Recession Fears

These five US stocks are defying market trends on new deals, technological breakthroughs, improved sectoral outlook, and strong fundamentals.

International Business Times UK

Rhythm Pharmaceuticals Stock Earns RS Rating Upgrade

Rhythm Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

Rhythm Pharmaceuticals Clears Key Benchmark, Hitting 80-Plus RS Rating

Rhythm Pharmaceuticals sees its Relative Strength Rating hit the 80-plus level.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Rhythm Pharmaceuticals Shows Rising Price Performance With Jump To 81 RS Rating

A Relative Strength Rating upgrade for Rhythm Pharmaceuticals shows improving technical performance.

Investors Business Daily

Rhythm Pharmaceuticals Clears Key Benchmark, Hitting 80-Plus RS Rating

Rhythm Pharmaceuticals sees its Relative Strength Rating move into the 80-plus level.

Investors Business Daily

Rhythm Pharmaceuticals Shows Market Leadership With Jump To 91 RS Rating

Rhythm Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 13 Analysts

Rhythm Pharmaceuticals (NASDAQ:RYTM) has been analyzed by 13 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Biotech Stock Attempts To End Losing Streak, Lands Back in Buy Zone

This biotech stock is back in a buy zone after a sharp sell-off. The company makes an obesity drug and develops treatments for rare diseases.

Investors Business Daily

Stocks To Watch: Rhythm Pharmaceuticals Sees Relative Strength Rating Jump To 93

Rhythm Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

Biotech Stock Near Buy Point Amid Impressive Sales Track Record

Rhythm Pharmaceuticals is near a buy point after strong sales in the second quarter.

Investors Business Daily

12 Health Care Stocks Moving In Thursday's Intraday Session

Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session

Gainers Enochian BioSciences (NASDAQ:ENOB) shares moved upwards by 27.8% to $2.3 during Wednesday's after-market session. The market value of their outstanding shares is at $121.7 million.

Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session

Benzinga

Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 176.5% to close at $31.00 on Thursday after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to shareholders.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Why Bilibili Is Trading Lower By Over Around 14%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 73.8% to $19.48 after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to shareholders.

Benzinga

AeroVironment, Snap And Some Other Big Stocks Moving Higher On Thursday

U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Thursday. Here are some big stocks recording gains in today’s session.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022

Upgrades

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session

Benzinga

Recap Of Friday's Biotech Catalysts - End Of The Day Summary

Bristol Myers Squibb (NYSE:BMY) received European Medicines Agency (EMA) Positive CHMP Opinion recommending approval for Opdualag (nivolumab and relatlimab) for treatment of patients with Unresectable or Metastatic Melanoma based on results from the Phase 2/3 RELATIVITY-047 trial. Bristol Myers shares traded in a range of $72.48 to $73.61 on a…

Investors Business Daily

Rhythm Has Tripled In A Week And Quintupled Since May — Here's Why

Rhythm Pharmaceuticals has announced a steady drumbeat of good news for its obesity treatment, leading RYTM stock to triple in a week.

Benzinga

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session

Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session

Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session

Gainers

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Investor Business Daily

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.